Local research. Human connections. WCR Miami Lakes (786) 483-7856
Back to study searchNCT07919743
Not yet recruitingNCT07919743ClinicalTrials.gov record

Efficacy of TECAR Therapy in Plantar Fasciitis

Plantar Fasciitis

THE QUICK READ

What this study involves

The registry does not currently label this study as recruiting. Ask about its status before planning a screening visit.

Study type
Interventional
Phase
Not applicable
Age range
18 years - 65 years
Sex eligible
All sexes
Healthy volunteers
Not accepted
Participants
60 Estimated

These are starting points, not an eligibility decision. The research team must review the full requirements.

About the research

This randomized, double-blind, sham-controlled clinical trial aims to evaluate the efficacy of Capacitive and Resistive Energy Transfer (TECAR) therapy combined with an exercise program in patients with plantar fasciitis. The effects of active TECAR therapy will be compared with those of sham TECAR therapy, both combined with the same exercise program, in terms of pain intensity, foot function, pressure pain threshold, ultrasonographic plantar fascia thickness, and health-related quality of life.

TECAR therapy is a non-invasive physical therapy modality used in musculoskeletal rehabilitation. Although it is increasingly used in clinical practice, evidence from sham-controlled randomized trials in patients with plantar fasciitis remains limited. This study aims to determine whether active TECAR therapy provides additional benefits over sham treatment when combined with exercise. The findings are expected to contribute to the evidence regarding the clinical efficacy of TECAR therapy in the management of plantar fasciitis.

Who may be able to participate?

The list below is the sponsor’s full registry wording. It can include conditions, prior treatment, test results and other requirements. A match in search does not mean you qualify.

Inclusion Criteria:

  • Adults aged 18-65 years
  • Clinical diagnosis of plantar fasciitis
  • Presence of tenderness over the medial calcaneal tubercle and/or morning first-step pain
  • Symptom duration of at least 3 months
  • Pain intensity ≥4 on the Visual Analog Scale (VAS)
  • Plantar fascia thickness ≥4.0 mm at the medial calcaneal insertion, measured by ultrasonography
  • Willingness to participate in the study and provision of written informed consent

Exclusion Criteria:

  • History of injection therapy, extracorporeal shock wave therapy (ESWT), or surgery for plantar fasciitis within the previous 3 months
  • Presence of systemic inflammatory rheumatic diseases
  • Diabetic neuropathy or peripheral neuropathy
  • Other conditions that may cause heel pain (e.g., stress fracture, infection, or tumor)
  • Pregnancy
  • Presence of a cardiac pacemaker or other implanted electronic device
  • Active infection or open wound at the treatment site
Understand screening

Treatment, groups and participation

The registry may describe treatments and study duration without a complete visit calendar. Ask the study team for the exact schedule, procedures, risks, costs and alternatives. Keep your usual care plan unless your treating clinician tells you otherwise.

Assignment
Random assignment
Masking
Double masked
Active TECAR Therapy + Exercise

Participants will receive active TECAR therapy for 15 minutes per session (5 minutes in capacitive mode and 10 minutes in resistive mode), 5 days per week for 2 weeks (10 sessions), using the BTL TECAR Therapy device. All participants will also perform a standardized exercise program consisting of plantar fascia and calf stretching and intrinsic foot muscle strengthening exercises.

Device: Capacitive and Resistive Energy Transfer (TECAR) therapy · Other: Standardized Exercise Program

Sham TECAR Therapy + Exercise

Participants will receive sham TECAR therapy using the same device and application procedure without therapeutic energy delivery, for 15 minutes per session, 5 days per week for 2 weeks (10 sessions). All participants will perform the same standardized exercise program as the active treatment group.

Device: Sham Capacitive and Resistive Energy Transfer (TECAR) Therapy · Other: Standardized Exercise Program

Capacitive and Resistive Energy Transfer (TECAR) therapy DEVICE

Active TECAR therapy will be administered using the BTL TECAR Therapy device for 15 minutes per session, 5 days per week for 2 weeks (10 sessions). Each session will consist of 5 minutes of capacitive mode followed by 10 minutes of resistive mode. Treatment will be applied along the plantar fascia of the symptomatic foot, focusing on the medial calcaneal insertion, using conductive cream and continuous probe movement. The intensity will be adjusted to produce a comfortable, mild thermal sensation without pain.

Sham Capacitive and Resistive Energy Transfer (TECAR) Therapy DEVICE

Sham TECAR therapy will be administered using the same device, probe, and application procedure as the active treatment for 15 minutes per session, 5 days per week for 2 weeks (10 sessions). The device will not deliver any energy during sham treatment. The application will otherwise be identical to the active treatment procedure.

Standardized Exercise Program OTHER

All participants will receive a standardized exercise program consisting of plantar fascia stretching, gastrocnemius and soleus stretching, and intrinsic foot muscle strengthening (short-foot exercises). Exercises will be performed three times daily. Stretching exercises will consist of 10 repetitions held for 10-15 seconds, while strengthening exercises will consist of 10-15 repetitions.

Prepare your questions

What researchers are measuring

Outcome measures describe what is being studied. They are not proof that a treatment works.

Primary measures

Morning First-Step Pain (VAS)

Time frame: Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion.

Morning first-step pain will be assessed using a 10-centimeter (cm) Visual Analog Scale (VAS). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more severe pain (a worse outcome). Changes in pain intensity will be evaluated from baseline to each follow-up time point.

Secondary measures

General Pain Intensity (VAS)

Time frame: Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion.

General pain intensity will be assessed using a 10-centimeter (cm) Visual Analog Scale (VAS). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more severe pain (a worse outcome).

Pain During Activity (VAS)

Time frame: Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion.

Pain during activity will be assessed using a 10-centimeter (cm) Visual Analog Scale (VAS). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more severe pain (a worse outcome).

Foot Function Index (FFI)

Time frame: Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion.

Foot-related pain, disability, and activity limitation will be evaluated using the Foot Function Index (FFI), which consists of pain, disability, and activity limitation subscales. The total score ranges from 0 to 100; higher scores indicate greater foot-related impairment (a worse outcome).

Pressure Pain Threshold (PPT)

Time frame: Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion.

Pressure pain threshold (PPT) will be measured using a pressure algometer at the most painful region of the plantar heel and recorded in kilograms per square centimeter (kg/cm²). Higher values indicate a higher pain threshold, i.e., lower pressure pain sensitivity (a better outcome).

Plantar Fascia Thickness

Time frame: Baseline (pre-treatment) and 6 weeks after treatment completion.

Plantar fascia thickness will be measured by ultrasonography at the calcaneal insertion and recorded in millimeters (mm). Greater thickness indicates more pronounced plantar fascia thickening (a worse outcome); a decrease in thickness indicates improvement.

Health-Related Quality of Life (EuroQol 5-Dimension 5-Level Questionnaire)

Time frame: Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion.

Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, which covers five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on five levels of severity. Responses will be converted into a single EQ-5D-5L index score using the United Kingdom (UK) time trade-off (TTO) value set (Rowen et al., 2026). The index score ranges from -0.567 (worst health state) to 1 (full health), where 0 represents a state equivalent to death and negative values represent states considered worse than death. Higher scores indicate better health-related quality of life (a better outcome).

No results are flagged as posted.

Review the complete result tables and limitations in the official record.

Open official results ↗

Research locations (1)

The overall study status and a local site’s status can differ. Confirm that location’s availability before traveling.

1 locations

Etlik City HospitalAnkara, Yenimahalle, Turkey (Türkiye)Status unknown

Study team and timeline

Lead sponsor
Ankara Etlik City Hospital
Study start
Nov 1, 2026 Estimated
Primary completion
Jun 30, 2027 Estimated
Study completion
Aug 30, 2027 Estimated
First posted
Nov 5, 2026 Actual
Last updated
Nov 10, 2026 Actual

Official study contacts

Gizem Suna Tuncer, MD, Specialist PhysicianCONTACTsunagizem05@gmail.com05347953185
Official study title

Efficacy of Capacitive and Resistive Energy Transfer (TECAR) Therapy in Plantar Fasciitis: A Randomized, Double-Blind, Sham-Controlled Clinical Trial

A HUMAN NEXT STEP

Ask Wellness Clinical Research

Your message goes to WCR, including when this study is run by another organization. WCR may offer general guidance but may not operate this trial, have access to its team or be able to enroll you.

Please do not include medical records, diagnoses, medications, insurance numbers or other sensitive details. This form is for general questions, not urgent care.

Sending a question does not enroll you in a trial.

Source: ClinicalTrials.gov API v2. Information is submitted by sponsors and investigators. NLM does not approve the safety or science of all listed studies. Registry disclaimer.

Retrieved: Nov 12, 2026 · Last registry update: Nov 10, 2026